In the context of several pharmaceutical companies that reported sales declines in the second quarter due to COVID-19, AstraZeneca represents a rare exception, thanks to the strong performance of its cancer drugs. In the second quarter, AZ’s oncology portfolio generated $ 2.61 billion, a 24% year-over-year increase with constant exchange …
Read More »IO blockbusters from Merck, BMS, and more related to poor COVID-19 results: study
In the month ending April 7, 423 cancer patients at Memorial Sloan Kettering Cancer Center were diagnosed with COVID-19, 20% of whom developed severe respiratory symptoms. That in itself was not surprising, given that cancer patients are immunocompromised and therefore face an increased risk of fighting the virus. But a …
Read More »